Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(10): 598-601
DOI: 10.1055/s-2005-872905
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Endothelin-1 Levels in Patients with Paget's Disease of Bone

R. Pirzer1 , 2 , N. Tilly1 , U. Sommer1 , U. Liegibel1 , I. Grafe1 , P. Nawroth1 , C. Kasperk1
  • 1Department of Medicine I, Ruprecht-Karls University Heidelberg, Heidelberg, Germany
  • 2Department of Medicine (Cardiology, Angiology, Pneumology), Faculty of Clinical Medicine Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
Further Information

Publication History

Received: April 19, 2005 First decision: July 8, 2005

Accepted: September 2, 2005

Publication Date:
30 November 2005 (online)

Also available at
    Permissions and Reprints

Abstract

A locally accelerated bone turnover is the pathophysiological basis of Paget's disease of bone (PD) and may result in severe bone deformations and pain. Affected bone sites are hypervascularized. Secreted endothelial products such as endothelin-1 (ET-1), influence bone metabolism. We investigated a possible correlation between ET-1 plasma concentrations and bone metabolism in patients with PD and whether ET-1 plasma levels are regulated by i. v. bisphosphonate treatment. Plasma ET-1 levels were determined in 22 patients with PD and found to be significantly (p = 0.006) elevated (0.75 ± 0.48 fmol/ml) compared to 19 healthy controls (0.20 ± 0.24 fmol/ml). In a group of five patients with PD, plasma ET-1 levels were determined before and after treatment with i. v. pamidronate. On the average, ET-1 levels decreased by 21 % after pamidronate infusions (p = 0.045). The results suggest that bone metabolism in pagetic bone affects endothelial cell metabolism and may also be modulated by endothelial cell products. ET-1 plasma levels may indicate PD activity.

Key words

Paget's disease - endothelin-1 - bone densitometry - bone turnover markers - bisphosphonates

References

  • 1 Alam A S, Gallagher A, Shankar V, Ghatei M A, Datta H K, Huang C L, Moonga B S, Chambers T J, Bloom S R, Zaidi M. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption.  Endocrinology. 1992;  130 3617-3624
    CrossrefPubMedGoogle Scholar
  • 2 Alvarez L, Ricos C, Peris P, Guanabens N, Monegal A, Pons F, Ballesta A M. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.  Bone. 2000;  26 571-576
    CrossrefPubMedGoogle Scholar
  • 3 Cawley M I. Complications of Paget's disease of bone.  Gerontology. 1983;  29 276-287
    PubMedGoogle Scholar
  • 4 Cherian R A, Haddaway M J, Davie M W, McCall I W, Cassar-Pullicino V N. Effect of Paget's disease of bone on areal lumbar spine bone mineral density measured by DXA, and density of cortical and trabecular bone measured by quantitative CT.  Br J Radiol. 2000;  73 720-726
    PubMedGoogle Scholar
  • 5 Coessens B C, Miller V M, Wood M B. Endothelin induces vasoconstriction in the bone vasculature in vitro: an effect mediated by a single receptor population.  J Orthop Res. 1996;  14 611-617
    CrossrefPubMedGoogle Scholar
  • 6 Cook G J, Blake G M, Marsden P K, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography.  J Bone Miner Res. 2002;  17 854-859
    CrossrefPubMedGoogle Scholar
  • 7 Eckhoff M, Klift M, Kroon H, Cooper C, Hofman A, Pols H, Papapoulos S. Paget's disease of bone in the Netherlands: A population-based radiological and biochemical survey - the Rotterdam Study.  J Bone Miner Res. 2004;  19 566-570
    PubMedGoogle Scholar
  • 8 Fogelman I, Bessent R G, Turner J G, Citrin D L, Boyle I T, Greig W R. The use of whole-body retention of Tc-99 m diphosphonate in the diagnosis of metabolic bone disease.  J Nucl Med. 1978;  19 270-275
    PubMedGoogle Scholar
  • 9 Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.  Cancer Res. 2002;  62 6538-6544
    PubMedGoogle Scholar
  • 10 Frelin C, Guedin D. Why are circulating concentrations of endothelin-1 so low?.  Cardiovasc Res. 1994;  28 1613-1622
    PubMedGoogle Scholar
  • 11 Gonzalez D C, Mautalen C A. Short-term therapy with oral olpadronate in active Paget's disease of bone.  J Bone Miner Res. 1999;  14 2042-2047
    PubMedGoogle Scholar
  • 12 Kasperk C, Helmboldt A, Borcsok I, Heuthe S, Cloos O, Niethard F, Ziegler R. Skeletal site-dependent expression of the androgen receptor in human osteoblastic cell populations.  Calcif Tissue Int. 1997;  61 464-473
    CrossrefPubMedGoogle Scholar
  • 13 Kasperk C H, Borcsok I, Schairer H U, Schneider U, Nawroth P P, Niethard F U, Ziegler R. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro.  Calcif Tissue Int. 1997 b;  60 368-374
    CrossrefPubMedGoogle Scholar
  • 14 Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y, Harii K. Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization.  J Bone Miner Res. 1998;  13 237-244
    PubMedGoogle Scholar
  • 15 Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension.  Can J Physiol Pharmacol. 2003;  81 607-621
    CrossrefPubMedGoogle Scholar
  • 16 Laroche M, Delpech B, Bernard J, Constantin A, Mazieres B. Measurement of bone mineral density by dual X‐ray absorptiometry in Paget's disease before and after pamidronate treatment.  Calcif Tissue Int. 1999;  65 188-191
    CrossrefPubMedGoogle Scholar
  • 17 Masukawa H, Miura Y, Sato I, Oiso Y, Suzuki A. Stimulatory effect of endothelin-1 on Na-dependent phosphate transport and its signaling mechanism in osteoblast-like cells.  J Cell Biochem. 2001;  83 47-55
    CrossrefPubMedGoogle Scholar
  • 18 Mathieu M N, Hamroun D, Launay J M, Chevillard C. Human bone marrow platelet progenitors express and release endothelin-1.  J Cardiovasc Pharmacol. 1998;  31 (Suppl 1) 509-511
    PubMedGoogle Scholar
  • 19 Meunier P J, Coindre J M, Edouard C M, Arlot M E. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue.  Arthritis Rheum. 1980;  23 1095-1103
    PubMedGoogle Scholar
  • 20 Michel R P, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension.  Can J Physiol Pharmacol. 2003;  81 542-554
    CrossrefPubMedGoogle Scholar
  • 21 Miyazaki T, Hirose N, Kawamura J, Kageyama Y, Iikuni K, Yanagishita T. A case of generalized Paget's disease of bone complicating high output heart failure.  Nippon Naika Gakkai Zasshi. 1983;  72 47-54
    PubMedGoogle Scholar
  • 22 Owen M. Marrow stromal stem cells.  J Cell Sci. 1988;  10 (Suppl) 63-76
    PubMedGoogle Scholar
  • 23 Roodman G D. Paget's disease and osteoclast biology.  Bone. 1996;  19 209-212
    CrossrefPubMedGoogle Scholar
  • 24 Roux C, Gennari C, Farrerons J, Devogelaer J P, Mulder H, Kruse H P, Picot C, Titeux L, Reginster J Y, Dougados M. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.  Arthritis Rheum. 1995;  38 851-858
    PubMedGoogle Scholar
  • 25 Rubanyi G M, Botelho L H. Endothelins.  FASEB J. 1991;  5 2713-2720
    PubMedGoogle Scholar
  • 26 Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET.  J Nucl Med. 1997;  38 1970-1976
    PubMedGoogle Scholar
  • 27 Schneider J G, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, Leidig-Bruckner G, Kasperk C. Elevated plasma endothelin-1 levels in diabetes mellitus.  Am J Hypertens. 2002;  15 967-972
    CrossrefPubMedGoogle Scholar
  • 28 Shioide M, Noda M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells.  J Cell Biochem. 1993;  53 176-180
    CrossrefPubMedGoogle Scholar
  • 29 Stern P H, Tatrai A, Semler D E, Lee S K, Lakatos P, Strieleman P J, Tarjan G, Sanders J L. Endothelin receptors, second messengers, and actions in bone.  J Nutr. 1995;  125 2028-2032
    PubMedGoogle Scholar
  • 30 Tarquini R, Perfetto F, Tarquini B. Endothelin-1 and Paget's bone disease: is there a link?.  Calcif Tissue Int. 1998;  63 118-120
    CrossrefPubMedGoogle Scholar
  • 31 Thiebaud D, Jaeger P, Gobelet C, Jacquet A F, Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.  Am J Med. 1988;  85 207-212
    PubMedGoogle Scholar
  • 32 Tilly N, Schneider J G, Leidig-Bruckner G, Sommer U, Kasperk C. Endothelin-1 levels in patients with disorders of the thyroid gland.  Exp Clin Endocrinol Diabetes. 2003;  111 80-84
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Tsukahara H, Hori C, Hiraoka M, Yamamoto K, Ishii Y, Mayumi M. Endothelin subtype A receptor antagonist induces osteopenia in growing rats.  Metabolism. 1998;  47 1403-1407
    CrossrefPubMedGoogle Scholar
  • 34 Vane J. Endothelins come home to roost.  Nature. 1990;  348 673
    PubMedGoogle Scholar
  • 35 Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels.  J Hypertens. 1988;  6 (Suppl) 188-191
    PubMedGoogle Scholar
  • 36 Yin J J, Mohammad K S, Kakonen S M, Harris S, Wu-Wong J R, Wessale J L, Padley R J, Garrett I R, Chirgwin J M, Guise T A. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.  Proc Natl Acad Sci USA. 2003;  100 10954-10959
    CrossrefPubMedGoogle Scholar
  • 37 Ziegler R, Holz G, Rotzler B, Minne H. Paget's disease of bone in West Germany. Prevalence and distribution.  Clin Orthop. 1985;  194 199-204
    PubMedGoogle Scholar

MD PhD Christian Kasperk

Department of Medicine I
Ruprecht-Karls University Heidelberg

Im Neuenheimer Feld 410

69120 Heidelberg

Germany

Phone: + 496221568605

Fax: + 49 62 21 56 68 65

Email: christian.kasperk@med.uni-heidelberg.de

      >